Albert David Ltd

Albert David Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 7 September 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. Despite robust quarterly earnings and a net-debt-free balance sheet, evolving technical indicators and valuation premiums have tempered enthusiasm among analysts.

Surging to an intraday peak of Rs 925 on 31 Aug 2026, Albert David Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This advance comes amid a three-day consecutive gain, delivering a 4.44% return over this short span and outperforming its sector by 1.59% today.

With a steady climb from Rs 581.30 to Rs 903.75 over the past year, Albert David Ltd has delivered a 10.90% return, outpacing the Sensex’s decline of 3.51%. This fresh 52-week high, reached on 28 Aug 2026, reflects a confluence of strong technical momentum and improving fundamentals within the Pharmaceuticals & Biotechnology sector.

Albert David Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy by MarketsMOJO as of 25 Aug 2026. This upgrade reflects a comprehensive improvement across four key parameters: Quality, Valuation, Financial Trend, and Technicals, underpinned by robust quarterly results and a bullish technical outlook.

The 50-day moving average has crossed above the 200-day moving average for Albert David Ltd, signalling a golden cross on 25 Aug 2026. Yet, the stock declined 1.87% on the same day, and monthly technical indicators show only mild bullishness, creating a nuanced picture that demands closer examination.

Albert David Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 07 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Albert David Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 7 August 2026. This change reflects significant improvements across financial performance, valuation metrics, and technical indicators, signalling a more favourable outlook for investors after a period of underperformance.

Albert David Ltd has witnessed a notable shift in its valuation parameters, moving from a risky to a fair valuation grade, reflecting an enhanced price attractiveness for investors within the Pharmaceuticals & Biotechnology sector. This upgrade accompanies a strong market performance and a re-rating by analysts, positioning the micro-cap stock as a hold with potential for further gains despite ongoing sector headwinds.

Albert David Ltd has delivered a markedly improved financial performance in the quarter ended June 2026, reversing previous flat trends with robust revenue growth and significant margin expansion. Despite lingering concerns over non-operating income dependency, the pharmaceutical micro-cap’s latest results signal a potential inflection point for investors.

Albert David Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 20 July 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 01 August 2026, providing investors with the latest view of the company’s position in the market.

Albert David Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 20 Jul 2026. This revision reflects deteriorating technical indicators, stagnant financial performance, and unfavourable valuation metrics, signalling heightened risk for investors.

Albert David Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 13 July 2026. This change is primarily driven by a shift in technical indicators, even as the company continues to grapple with flat financial performance and poor long-term growth metrics.